4 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
PURPOSE Tovorafenib is an oral, selective, CNS-penetrant, type II inhibitor of BRAF and CRAF. BRAF fusions and CRAF/RAF1 fusions and amplifications are rare oncogenic drivers in many solid tumors. The phase II DAY101-102a substudy of FIRELIGHT-1 (ClinicalTrials.gov identifier: NCT04985604) investigated the efficacy and...
Simple Summary Melanoma is a serious skin cancer, and in East Asian patients it frequently arises at acral sites or on internal mucosal surfaces rather than on sun-exposed skin. These forms tend to respond less well to immunotherapy, the current standard first-line treatment, yet it remains unclear which tumors benefit...
In metastatic disease, EOCRC shares a conserved canonical genomic backbone with AOCRC, indicating that it is not a genomically distinct entity, which suggests that CRC arising at younger age may reflect distinct age-associated biological vulnerabilities.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
